Tscan Therapeutics Ownership

TCRX Stock  USD 1.24  0.07  5.34%   
The majority of Tscan Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tscan Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tscan Therapeutics. Please pay attention to any change in the institutional holdings of Tscan Therapeutics as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as Tscan Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tscan Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Tscan Stock Ownership Analysis

About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.33. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tscan Therapeutics recorded a loss per share of 1.08. The entity last dividend was issued on the 13th of September 1970. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people. To find out more about Tscan Therapeutics contact the company at 857 399 9500 or learn more at https://www.tscan.com.

Tscan Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tscan Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tscan Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tscan Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
David Southwell over a month ago
Acquisition by David Southwell of 15000 shares of Tscan Therapeutics at 3.6226 subject to Rule 16b-3
 
Gruia Gabriela over a month ago
Acquisition by Gruia Gabriela of 9146 shares of Tscan Therapeutics subject to Rule 16b-3
 
Klencke Barbara over a month ago
Acquisition by Klencke Barbara of 5000 shares of Tscan Therapeutics at 5.69 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over two months ago
Acquisition by Baker Bros. Advisors Lp of 758094 shares of Tscan Therapeutics at 1.95 subject to Rule 16b-3
 
Lynx1 Capital Management Lp over three months ago
Acquisition by Lynx1 Capital Management Lp of 31800 shares of Tscan Therapeutics at 3.0072 subject to Rule 16b-3
 
Lynx1 Capital Management Lp over six months ago
Disposition of 10000 shares by Lynx1 Capital Management Lp of Tscan Therapeutics at 2.5148 subject to Rule 16b-3
 
Klencke Barbara over six months ago
Acquisition by Klencke Barbara of 5000 shares of Tscan Therapeutics at 5.29 subject to Rule 16b-3
 
Klencke Barbara over six months ago
Acquisition by Klencke Barbara of 5000 shares of Tscan Therapeutics at 5.53 subject to Rule 16b-3
 
Zdraveski Zoran over six months ago
Disposition of 164686 shares by Zdraveski Zoran of Tscan Therapeutics at 5.7814 subject to Rule 16b-3
 
Westphal Christoph H over six months ago
Disposition of 171063 shares by Westphal Christoph H of Tscan Therapeutics subject to Rule 16b-3
 
Silver Brian M. over six months ago
Acquisition by Silver Brian M. of 5885 shares of Tscan Therapeutics at 8.4835 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Acquisition by Baker Bros. Advisors Lp of 47500 shares of Tscan Therapeutics at 8.88 subject to Rule 16b-3

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.